Lower expression of Bax predicts poor clinical outcome in patients with glioma after curative resection and radiotherapy/chemotherapy
Open Access
- 16 November 2018
- journal article
- research article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 141 (1) , 71-81
Abstract
Background The prognosis in patients with gliomas after surgical resection followed by radiotherapy and/or chemotherapy is still very poor. The pro-apoptotic protein Bax, a short-lived protein in cancers, plays important roles in the sensitivity of glioma cells to spontaneous and therapy-induced apoptosis but and its prognostic value in gliomas is unknown. Methods By an immunohistochemical method, we determined Bax protein expression from 96 patients with gliomas after curative resection. Two statistical analyses were performed to evaluate the prognostic significance of Bax protein: an independent continuous and a multivariate categorical analysis, with test/validation set-defined cut points, and Kaplan–Meier estimated outcome measures of overall survival (OS) and relapse-free survival (RFS). Results Bax protein levels in glioblastoma were significantly decreased compared with grade II gliomas. Lower levels of Bax expression confer worse OS (continuous P = 0.025; categorical P = 0.003) and RFS (continuous P = 0.014; categorical P < 0.0001) and negatively correlate with the grades of gliomas. Patients underwent radiotherapy followed by surgical resection showed significantly increased OS (median = 45 vs. 17 months) and RFS (median = 39 vs. 16 months). Patients with higher levels of Bax and radiotherapy showed greatly increased survival rates (median OS = 66 months and median RFS = 105 months). Lower expression of Bax also confers inferior clinical outcome for gliomas patients after chemotherapy with temozolomide (OS and RFS P < 0.0001). Conclusion Decreased expression of Bax correlates with poor clinical outcome in patients with gliomas. We propose that Bax protein levels can be used as a reliable prognostic marker for risk-stratify patients with gliomas after curative resection and radiotherapy and/or chemotherapy.Keywords
Funding Information
- National Natural Science Foundation of China (81172109, 81570191, 81570194)
This publication has 43 references indexed in Scilit:
- Randomized Trial of Radiation Therapy Plus Procarbazine, Lomustine, and Vincristine Chemotherapy for Supratentorial Adult Low-Grade Glioma: Initial Results of RTOG 9802Journal of Clinical Oncology, 2012
- Bax expression measured by AQUAnalysis is an independent prognostic marker in oral squamous cell carcinomaBMC Cancer, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working GroupJournal of Clinical Oncology, 2010
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Low Expression of Bax Predicts Poor Prognosis in Resected Non-small Cell Lung Cancer Patients with Non-squamous HistologyJapanese Journal of Clinical Oncology, 2008
- Comprehensive genomic characterization defines human glioblastoma genes and core pathwaysNature, 2008
- Increased proteasomal degradation of Bax is a common feature of poor prognosis chronic lymphocytic leukemiaBlood, 2008
- Prognostic significance of bcl‐2, bax, and p53 expression in diffuse large B‐cell lymphomaAmerican Journal of Hematology, 2003
- Overexpression of bax in human glioma cell linesJournal of Neurosurgery, 1999